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Abstract
Discovered in 1986 as a DNA binding activity that recognized the immunoglobulin light chain intronic enhancer, NF-UB
has been studied intensively for its role in controlling expression of genes involved in immune and inflammatory function
[1,2]. However, more recently, NF-UB has been implicated in controlling cell growth and oncogenesis. The link between NF-
UB and cancer stems, in part, from the fact that this transcription factor is capable of inducing gene products that control
proliferative responses and that suppress apoptotic cascades, such as those induced by tumor necrosis factor (TNF),
expression of oncoproteins, and genotoxic stress. This latter observation is likely to be important in developing new
approaches aimed at improving the efficacy of cancer chemotherapy. ß 2000 Elsevier Science B.V. All rights reserved.
1. Activation and regulation of NF-UB
NF-UB factors are dimers of Rel family of pro-
teins. There are presently ¢ve members of the NF-
UB family: p50/p105 (NF-UB1), p52/p100 (NF-UB2),
c-Rel, RelB, and p65 (RelA). These proteins are
characterized by their Rel homology domains which
control DNA binding, dimerization and interactions
with inhibitory proteins known as IUB (reviewed in
[1,2]). Several IUB genes (IUBK, IUBL, IUBO) have
been identi¢ed and their gene products have been
shown to function to retain NF-UB proteins in the
cytoplasm [1,2]. The IUB proteins physically interact
with NF-UB to block the nuclear localization sequen-
ces of NF-UB, thus regulating both transient and
persistent nuclear levels of NF-UB. Another member
of the IUB family, Bcl-3, interacts with p50 and p52
subunits of NF-UB, but rather than functioning to
inhibit NF-UB transcriptional activity, Bcl-3 func-
tions to stimulate transcription and to promote nu-
clear localization [1,2]. In most cell types, NF-UB
complexes are largely cytoplasmic and transcription-
ally inactive until a cell receives the appropriate stim-
uli. In response to pro-in£ammatory cytokines, such
as TNF and interleukin-1 (IL-1), or bacterial lipopo-
lysaccharide (LPS) the IUB proteins become phos-
phorylated on two serine residues located within
the N-terminal region [1,2]. Phosphorylation occurs
on Ser-32 and Ser-36 of IUBK and on Ser-19 and Ser-
23 of IUBL. Phosphorylation of the IUB proteins re-
sults in rapid ubiquitination and subsequent proteol-
ysis by the 26S proteasome. Proteasome-dependent
degradation of the IUB proteins results in the libera-
tion of NF-UB allowing this transcription factor to
accumulate in the nucleus where it activates the ex-
pression of speci¢c gene targets [1,2].
Recently, a large molecular weight complex re-
sponsible for phosphorylating IUBK and IUBL was
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puri¢ed and genes encoding several of the protein
subunits were identi¢ed (reviewed in [3^5]). The ¢rst
two subunits to be identi¢ed were called IUB kinase
(IKK) K and L. These two proteins contain a Ser/Thr
kinase domain in the N-terminal portion of the pro-
tein, a leucine zipper, which is responsible for heter-
odimer formation, and a helix-loop-helix domain in
the carboxy-terminal region. Although these proteins
can form stable homodimers in vitro, it is believed
that the majority of the kinase activity is associated
with the formation of IKKK/IKKL heterodimers. In
addition to IKKK and IKKL, another protein sub-
unit has also been associated with the IKK complex
called IKKQ or NEMO (NF-UB essential modulator).
IKKQ is present in the IKK complex and is essential
for IKKK/IKKL kinase activity perhaps by acting as
a structural complex that links the IKK complex to
upstream signaling pathways (reviewed in [4,5]).
In addition to IUB-dependent regulation, NF-UB
transcriptional activity is also positively modulated
through signaling events that result in direct phos-
phorylation of NF-UB subunits. For example, it has
been shown [6] that phosphorylation on Ser-276 by
the catalytic subunit of protein kinase A (PKAC) can
contribute to the intrinsic transcriptional capacity of
the p65 subunit of NF-UB. Interestingly, PKAc was
found associated with NF-UB and IUB in the cyto-
plasm and was able to phosphorylate p65 only after
IUB degradation [6]. The phosphorylation of p65 on
Ser-276 increases intrinsic transcriptional activity by
facilitating interaction with the transcriptional co-ac-
tivators, CBP (cAMP-responsive element binding
protein (CREB)-binding protein) and the closely re-
lated factor p300 [6]. Our laboratory has also dem-
onstrated that TNF can stimulate signaling cascades
that lead to the phosphorylation of the p65 in the C-
terminal transactivation domain 1 (TAD1) on Ser-
529 [7]. Similar to phosphorylation on Ser-276,
TNF-induced phosphorylation of p65 at Ser-529
does not a¡ect nuclear translocation signals or mod-
ulate DNA-binding activity but instead increases the
transcriptional potential of p65. Interestingly, a site-
directed mutant of p65 (Ser-276 to Ala) is still phos-
phorylated at Ser-529 in response to TNF treatment
[7], suggesting that multiple physiological stimuli
modulate p65 through distinct phosphorylation sites
to control transcriptional activity. Since the C-termi-
nus of p65 has been shown to interact with basal
transcriptional apparatus proteins like TBP, TFIIB,
and TAF105 as well as coactivators, including CBP
and p300 [1,2,6], it remains to be elucidated whether
the phosphorylation status of the TAD1 domain is
involved with regulating interactions with these reg-
ulatory proteins. Therefore, as with several transcrip-
tion factors, NF-UB is under dual control through
mechanisms which govern the regulation of nuclear
levels and others which modulate intrinsic transcrip-
tional capacity.
2. NF-UB is activated during oncogenic
transformation and tumorigenesis
Accumulating evidence indicates that NF-UB plays
an important role in the development of cancer and
metastasis. Retroviruses that encode v-Rel, a viral
homolog of c-Rel, are highly oncogenic and cause
aggressive tumors in chickens (reviewed in [8,9]). In-
terestingly, genes that encode c-Rel, NF-UB2 (p100/
p52), p65/RelA and Bcl-3 proteins are all locat-
ed within regions of the genome that are involved
in rearrangements or ampli¢cations. The gene for
c-Rel has been found ampli¢ed in some cancer
cell lines and rearranged in others [8,9]. The Bcl-3
gene was originally identi¢ed as a [t(14,19)
(q32;q13.1)]chromosomal translocation in a subset
of B-cell chronic lymphocytic leukemias [10] and is
overexpressed in certain B-cell neoplasms [11]. The
t(10,14) chromosomal translocation breakpoint asso-
ciated with NF-UB2 originally found in a case of B-
cell non-Hodgkin’s lymphoma [12] is found in num-
ber of lymphoid neoplasms, particularly cutaneous
lymphomas [13]. Moreover, expression of lympho-
ma-associated, but not normal p52, induced tumori-
genic potential in 3T3 cells in a SCID mouse experi-
ment [14]. In another experiment, it was shown that
mice with a homozygous deletion of the C-terminal
ankyrin repeats of the p100 precursor exhibited in-
creased lymphocyte proliferation and gastric hyper-
plasia [15]. Mutations in the IUBK gene have been
detected in Hodgkin’s lymphoma [16] and are sug-
gested to contribute to constitutively active NF-UB in
Hodgkin’s cells. This observation suggests a tumor
suppressor for this inhibitory protein as well as an
involvement of NF-UB in this disease (also see be-
low).
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NF-UB is also directly linked to cellular transfor-
mation independent of chromosomal translocation
events. For example, it has been shown that NF-UB
is activated by a number of viral transforming pro-
teins and, in some cases, is required for virus-induced
transformation. Thus, the Tax protein from the hu-
man T-cell leukemia virus-I (HTLV-I) transcription-
ally activates NF-UB. It appears that Tax activates
NF-UB through direct interactions with the IKK
complex [17^21]. Activation of NF-UB was shown
to be required for transformation of rat ¢broblasts
by the HTLV-I Tax protein [22]. In addition, other
viral transforming proteins, such as the Epstein^Barr
virus (EBV) encoded proteins, EBV protein nuclear
antigen 2 (EBNA2) and the latent membrane protein
(LMP), the Simian virus-40 (SV-40) encoded large-T,
and adenovirus encoded E1A, all stimulate NF-UB
transcriptional activity [23]. Consistent with NF-UB
being involved in transformation and tumorigenesis,
many human derived solid tumor cell lines display
increased nuclear levels and/or increased NF-UB-de-
pendent reporter activity in comparison to non-
transformed control cell lines [24^27].
More recent evidence con¢rms the involvement of
NF-UB in oncogenesis. First, it was shown that in-
hibition of NF-UB by expression of a modi¢ed form
of IUBK (super-repressor IUBK) blocked focus forma-
tion induced by oncogenic H-Ras in NIH3T3 cells
[28]. Second, it was shown that the oncogenic fusion
protein BCR-ABL activated NF-UB and that tumori-
genesis driven by BCR-ABL could be blocked by
expression of the super-repressor IUBK [29]. Addi-
tionally, NF-UB was shown to be activated in Hodg-
kin’s lymphoma and inhibition of NF-UB blocked
growth of these cells [26]. As mentioned earlier, there
are numerous reports of NF-UB being activated in a
variety of tumor cell lines grown in vitro (see [24^
27]). For example, the classic form of NF-UB (p50-
p65) has been shown to be activated (i.e. nuclear) in
breast cancer cell lines and in some breast tumors
[25]. We agree with the observations that NF-UB
appears to be dysregulated in breast cancer, but in
contrast to these studies, we ¢nd that human breast
tumors display an accumulation of nuclear p52 and
Bcl-3 rather than p65 [30]. More evidence for the
involvement of NF-UB in cellular transformation
comes from Nancy Colburn and colleagues who
¢nd that AP-1 and NF-UB cooperate to promote
proliferation and transformation [31,32]. Recently it
has been shown that inhibition of NF-UB in head
and neck squamous cell carcinoma inhibits cell sur-
vival and tumor growth [27].
3. How do oncogene products activate NF-UB?
The ability of oncogenic Ras and Raf to activate
NF-UB has been intensively studied by our group
and others. Compared to parental control cells,
NF-UB nuclear levels were not increased in Ras- or
Raf-transformed cells even though an NF-UB-de-
pendent reporter exhibited a strong increase in activ-
ity in the transformed cells [28,33]. This enigma was
explained by showing that Raf- and Ras-transformed
cells display elevated NF-UB transcriptional activity
through the ability of these oncoproteins to target
the transactivation domain of the p65 subunit of
NF-UB [28,33]. Surprisingly, it was shown that dom-
inant negative forms of Raf did not strongly inhibit
the ability of Ras to activate NF-UB-dependent tran-
scription [33]. Thus, it was concluded that the major
pathway through which oncogenic Ras activated
NF-UB did not go through Raf. Several mechanisms
have been found to potentially explain this result.
First, inhibitors of the stress-activated kinase, p38
[33,34], and of the kinase, Akt (L. Madrid, A.B.
and M.M., submitted), block the ability of Ras
and/or Raf to activate NF-UB. Akt is downstream
of PI3K and is associated with promotion of cell
survival (reviewed in [35]). In each of these cases,
the activation of NF-UB-dependent expression is as-
sociated with the stimulation of p65 transcriptional
activity. Second, the ability of Raf to activate NF-UB
appears to involve the secretion of an autocrine fac-
tor which stimulates NF-UB transcriptional activity
[33,34]. Additionally, it has been found that induc-
tion of oncogenic Ras can stimulate a transient ac-
cumulation of NF-UB via the induction of IKK ac-
tivity (L. Madrid, A.B. and M.M., submitted). The
ability of oncogenic Ras to activate IKK may be
dependent on Akt, since other groups have recently
indicated that Akt can function to activate NF-UB in
an IKK-dependent manner [36^38]. However, Akt
activity, alone, is insu⁄cient to induce NF-UB nu-
clear translocation (L. Madrid, A.B. and M.M., sub-
mitted). Additionally, we have found that the ability
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of Akt to stimulate p65 transcriptional activity (not
involving induced nuclear translocation) is at least
partially dependent on IKK function (L. Madrid,
A.B. and M.M., submitted). Current work in the
laboratory is directed towards understanding the sig-
naling pathways utilized by Ras to potentially stim-
ulate phosphorylation of the p65 C-terminal trans-
activation domain.
In addition to Ras and Raf, other oncogene prod-
ucts are known to activate NF-UB. For example and
as described above, HTLV-I Tax activates NF-UB at
least partly through binding to IKK and stimulating
nuclear translocation of NF-UB [17^21]. Her2/Neu is
known to activate an NF-UB-dependent reporter
[39], but it was not shown whether this was through
nuclear accumulation of NF-UB or through stimula-
tion of transactivation function. The BCR-ABL on-
coprotein involved in chronic myelogenous leukemia
is known to activate NF-UB through a relatively
weak stimulation of nuclear translocation and
through the targeting of the transcriptional activa-
tion domain [29].
4. What is the role of NF-UB in oncogenesis?
Relevant to issues involving oncogenesis and re-
sistance to chemotherapy, it has been shown that
NF-UB activation can suppress cell death pathways
[40]. Thus, consistent with the role of NF-UB as an
anti-apoptotic factor, NF-UB activation is required
to protect cells from the apoptotic cascade induced
by TNF and other stimuli [41^45]. NF-UB has been
shown to activate TRAF1 and 2 and c-IAP1 and 2 to
block caspase-8 activation [46]. Other anti-apoptotic
genes have been shown to be activated by NF-UB
and include the Bcl-2 homolog A1/B£-1, IEX-1,
and XIAP [47^51]. Of signi¢cant interest are the ob-
servations that NF-UB can antagonize p53 function,
possibly through the cross-competition for transcrip-
tional co-activators [52].
Based on the observations which demonstrate that
cells upregulate NF-UB in response to TNF in order
to overcome apoptosis, we speculated that one mech-
anism whereby NF-UB functions to promote onco-
genesis was to suppress a transformation-associated
apoptosis. Thus, we tested whether NF-UB was re-
quired to suppress the apoptotic potential associated
with oncogenic H-Ras expression. Inhibition of NF-
UB, via the expression of the super-repressor IUBK,
led to the induction of apoptosis when an oncogenic
allele of H-Ras (RasV12) was expressed [53]. Other
evidence has been presented that inhibition of NF-UB
in transformed cells can induce apoptosis (see
[25,54]). In addition to being required to suppress
transformation-induced apoptosis, we and others
have recently shown that NF-UB can promote cell
growth through the transcriptional upregulation of
the cyclin D1 gene [55,56]. Since NF-UB has potent
e¡ects on cell survival and growth, NF-UB most
likely will also be found to control other aspects of
cell cycle progression. Relative to other aspects of
oncogenic control, NF-UB is known to regulate ex-
pression of cell adhesion molecules [1,2] and cell sur-
face proteases (such as MMP-9, [57]). Therefore, it is
speculated, but not proven, that NF-UB can control
metastasis. This idea is supported by the fact that
Cdc42 and Rac induce integrin-mediated invasive-
ness through PI3K [58], and we and others have
shown that Rac and PI3K are involved in NF-UB
activation (see above). Recently, it was shown that
animals null for TNF are inhibited in their ability to
undergo skin carcinogenesis [59]. Since NF-UB pos-
itively upregulates TNF gene expression and since
TNF activates NF-UB [1,2], these results [59] may
correlate with a role for NF-UB in skin carcinogene-
sis (see below, however). Consistent with this, it has
been suggested that the upregulation of NF-UB in
squamous cell carcinoma of the head and neck pro-
motes proin£ammatory cytokine production and
possibly metastasis [27,60].
Gene regulation by NF-UB is presumed to control
its major oncogenic functions. As described above,
NF-UB activates an anti-apoptotic response that sup-
presses the ability of oncogenic Ras to induce apop-
tosis. Additionally, it has been shown that the acti-
vation of NF-UB by growth factors suppresses the
apoptotic response induced by c-myc expression dur-
ing growth factor deprivation [38]. It is presently
unclear which of the anti-apoptotic genes that are
regulated by NF-UB may perform this function.
However, it should be noted that most tumors exhib-
it a general resistance to cell death pathways and the
upregulation of anti-apoptotic genes is most likely
relevant to the development of oncogenesis. For ex-
ample, members of the IAP family of anti-apoptotic
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proteins are upregulated in a variety of cancers [61],
and it is known that NF-UB regulates expression of
some of the IAP genes (see above). Additionally, as
stated above, NF-UB promotes cell-cycle progression
via the upregulation of cyclin D1.
What other NF-UB-regulated genes may contrib-
ute to oncogenesis? It has been reported that NF-UB
regulates the gene encoding tenascin-C, an extracel-
lular matrix protein involved in cell attachment and
cell growth [62]. NF-UB is known to regulate ICAM-
1 [1,2], a cell adhesion molecule found upregulated in
several cancers. For example, ICAM-1 is upregulated
in approximately 70% of primary melanoma lesions
and in about 90% of metastatic lesions [63]. ICAM-1
expression was associated with a reduction in dis-
ease-free intervals and in patient survival [63]. Cox-
2, a protein involved in in£ammation, is found up-
regulated in more aggressive forms of colorectal can-
cer [64], is known to be transcriptionally activated by
NF-UB [1,2] and is known to promote angiogenesis
[65]. The upregulation of iNOS and the enhanced
production of nitric oxide has also been proposed
to enhance tumor progression and angiogenesis
[66,67]. NF-UB has also been shown (reviewed in
[1]) to induce expression of the c-myc and c-myb
proto-oncogenes and of groK (melanoma stimulatory
factor). Hypoxia is present in regions of malignant
tumors and is thought to in£uence tumor progres-
sion through angiogenic processes [68] and hypoxia/
reperfusion is known to induce NF-UB activation
(see [1]). Thus, the activation of NF-UB may contrib-
ute to a pro-malignant phenotype by upregulating
gene products that control cell adhesion and angio-
genesis in addition to those promoting cell prolifer-
ation and survival.
5. NF-UB is a target of chemopreventive compounds
Evidence that NF-UB is involved in many in£am-
matory diseases (see [1,2] and in oncogenesis has led
a number of investigators to determine if NF-UB is a
speci¢c target of pharmaceutical and dietary com-
pounds known to prevent disease. Thus, it has been
shown that NF-UB is inhibited by aspirin or other
non-steroidal anti-in£ammatory drugs (NSAIDs)
treatments [69^71], which are known to block the
initiation and/or progression of certain cancers, par-
ticularly colorectal cancer (reviewed in [71]). Interest-
ingly, aspirin and sulindac both inhibit the activation
of the IUB kinase complex (see [70,71]). Several diet-
ary chemopreventive compounds, including £avo-
noids, curcumin, and resveratrol, are known to block
NF-UB activation ([72,73] and M. Holmes-McNary
and A.B., submitted). These studies make it likely,
therefore, that NF-UB is a functionally relevant tar-
get of chemopreventive drugs and dietary com-
pounds which prevent cancer.
6. Roles for NF-UB as a tumor suppressor and in
pro-apoptotic signaling
Although there is clear data that NF-UB is in-
volved in many aspects of oncogenesis, in part, by
the ability of this transcription factor to block apop-
tosis, there is evidence in the literature that indicates
that NF-UB may prevent oncogenesis and promote
apoptosis. Recently it was shown that inhibition of
NF-UB in the skin via expression of the super-re-
pressor form of IUBK led to squamous cell carcino-
mas and increased apoptosis [74]. Since NF-UB along
with IKKK has been proposed to be involved in con-
trolling di¡erentiation of skin [4,75], the loss of NF-
UB may promote oncogenesis in this particular set-
ting. Again, it is likely that the subunit composition
of NF-UB is important in determining relevant as-
pects of cellular growth control. Potentially relevant
to this point and, as described above, the activation
of NF-UB that occurs in breast cancer is not the p50-
p65 heterodimer but rather complexes that contain
p50, p52 and Bcl-3 [30]. Thus, di¡erent NF-UB com-
plexes may control growth and di¡erentiation in dif-
ferent cell types or in response to di¡erent stimuli.
Consistent with idea that NF-UB activation can
promote pro-apoptotic e¡ects, the gene encoding
Fas ligand (FasL) has been shown to be transcrip-
tionally regulated by both AP1 and NF-UB in re-
sponse to chemotherapeutic agents and to T-cell ac-
tivation signals [76,77]. In these studies, T-cells can
be induced to undergo apoptosis in response to eto-
poside or T-cell activation signals through the NF-
UB-dependent upregulation of FasL. Thus, the inhib-
ition of NF-UB provided cell protection from geno-
toxic-induced or T-cell activation-induced Fas-di-
rected death signalling [76,77]. Consistent with the
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dysregulated NF-UB transcriptional activity in hu-
man cancers, some transformed cells derived from
solid tumors display constitutive FasL expression
[78]. Interestingly, these cells are resistant to Fas-in-
duced apoptosis, because they either downregulate
Fas expression or they have intracellular mechanisms
to suppress Fas-induced apoptosis [78]. In fact, it has
been shown that oncogenic Ras downregulates Fas
gene expression [79]. Thus, overexpression of FasL
has been proposed to be a potential mechanism by
which solid tumors avoid the cellular immune system
by inducing Fas-mediated apoptosis in tumor in¢l-
trating T-cells. It is intriguing to speculate that the
activation of NF-UB in tumor cells could lead to
upregulation of FasL expression as well as the asso-
ciated resistance to apoptosis.
7. A role for NF-UB in chemoresistance
The realization that NF-UB can inhibit apoptosis
led us to examine whether NF-UB plays a role in
blocking the e⁄cacy of cancer chemotherapies and
radiation. Since NF-UB is activated in a number of
cancers, it may be that it provides a level of chemo-
resistance prior to cancer therapy. Additionally, we
showed [41] that HT1080 ¢brosarcoma cells exposed
to ionizing radiation and to the chemotherapy dau-
norubicin exhibited enhanced activation of NF-UB.
Inhibition of NF-UB leads to dramatically enhanced
apoptosis in response to ionizing radiation or dau-
norubicin treatment as compared to the control cells.
HT1080 ¢brosarcoma tumors grown in nude mice
were induced to undergo apoptosis when infected
with an adenovirus expressing a modi¢ed form of
IUBK along with systemic delivery of chemotherapy
CPT-11 [80]. Other tumors (for example, those de-
rived from the colorectal tumor cell line, LOVO)
showed basically identical responses to the combined
treatment. In fact, LOVO tumors could be elimi-
nated with CPT-11 systemic treatment and with ad-
enoviral delivery of IUBK either every 5 or 10 days (J.
Cusack, R. Liu and A.B., submitted). In contrast to
our studies, Bours and colleagues showed that stable
expression of the super-repressor form of IUBK did
not yield enhanced cytotoxicity in response to che-
motherapy, despite the ability of genotoxic agents to
activate NF-UB [81]. We have analyzed two of the
cell lines used in these in vitro studies, and have
found that transient inhibition of NF-UB via the ad-
enoviral delivery of IUBK strongly enhanced the
apoptotic response to CPT-11 ([82] and J. Cusack,
R. Liu and A.B., submitted). Thus, we propose that
the stable inhibition of NF-UB via the expression of
IUBK may select for variant cell types that have up-
regulated an NF-UB-independent anti-apoptotic
pathways. This concept is supported by the fact
that numerous cancer cells die upon infection with
the super-repressor form of IUBK (M.M., unpub-
lished and see [54]). Thus, the only consistent way
to block NF-UB in these types of experiments is
through transient inhibition of NF-UB, which is the
way that it must be accomplished in future develop-
ments of cancer therapy. Present studies are focused
on the treatment of a variety of cancers with systemic
(small molecule) inhibitors of NF-UB in combination
with chemotherapy.
8. Summary
The activation of NF-UB by virtually every known
oncogene product is consistent with a role for this
transcription factor in oncogenesis. Direct evidence,
using both in vitro and in vivo models, indicates that
NF-UB is required for oncogenesis probably at multi-
ple levels. Our evidence is that NF-UB plays an im-
portant role in the early events of oncogenesis, prob-
ably functioning primarily in protecting against
transformation-associated apoptosis. In most late
stage tumor cells, NF-UB is clearly not the only sur-
vival factor, because its inhibition does not induce
apoptosis in many of these tumor cells. This obser-
vation suggests that other secondary events have oc-
curred to upregulate NF-UB-independent cell surviv-
al pathways. Additionally, NF-UB contributes to cell
progression through the upregulation of cyclin D1
with the corresponding hyperphosphorylation event
on the tumor suppressor protein, Rb. NF-UB activa-
tion also potentiates proliferation by blocking di¡er-
entiation in certain settings, and this phenomenon
may also promote oncogenesis. NF-UB is known to
regulate certain genes associated with metastasis,
such as MMP9, tissue plasminogen activator, and
ICAM-1. Thus, a more relevant role for NF-UB in
later stage oncogenesis may be to promote metastasis
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and angiogenesis. Although many tumor cells display
elevated nuclear NF-UB, the transcriptional potential
of NF-UB appears to be further upregulated in re-
sponse to certain types of chemotherapy. Inhibition
of NF-UB in parallel with chemotherapy treatment
strongly enhances the apoptotic potential of the che-
motherapy. This observation indicates that NF-UB
plays an important role in inducible chemoresistance
and establishes NF-UB inhibition as an important
new adjuvant approach in chemotherapy.
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